Award of Shares under Share Incentive Plan
Creo Medical Group plc has announced transactions under its Share Incentive Plan (SIP) where Fiduchi Trustees acquired 143,541 ordinary shares at £0.144 each, triggering the issuance of 287,082 matching shares, which were satisfied from existing holdings. Executive directors Craig Gulliford and Richard Rees participated, with Gulliford acquiring 6,250 partnership shares at £0.144 and receiving 12,500 matching shares at £0.001, bringing his total holding to 2,062,385 shares. Richard Rees also acquired 6,250 partnership shares at £0.144 and received 12,500 matching shares at £0.001, increasing his total to 3,417,079 shares.
Select text to share a quote on X · sign in to keep highlights & notes in your CREO notes
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, implemented an HMRC approved Share Incentive Plan ("SIP") during 2020, which is available to all of the Company's UK based employees, including Directors.
The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"), the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 143,541 ordinary shares in the Company ("Ordinary Shares"), at a price of £0.144 per Ordinary Share on 1 July 2026 to meet its obligations under the SIP (the "Partnership Shares"). Under the terms of the SIP, the Company is required to issue or make available to the SIP, to be allocated to participants, two Ordinary Shares in the Company for each Partnership Share purchased (being 287,082 Ordinary Shares, the "Matching Shares"). As at 1 July 2026, Fiduchi held 875,247 unallocated Ordinary Shares within the SIP. 287,082 of these unallocated Ordinary Shares will be utilised to meet the SIP Matching Share obligation and, accordingly, no new Ordinary Shares are required to be issued to satisfy the Company's obligations under the SIP.
Craig Gulliford and Richard Rees, executive directors of the Company (the "Participating Directors"), have acquired Partnership Shares at a price of £0.144 per share at Fiduchi's sole discretion and received Matching Shares at a price of £0.001 per share in accordance with terms of the SIP (the "Transaction"). Following the Transaction, the Participating Directors' shareholdings in the Company are as set out in the table below:
| Director | Total number of Ordinary Shares purchased or awarded under SIP | Total number of Ordinary Shares held post Transaction |
|---|---|---|
| Craig Gulliford, CEO | 18,750 | 2,062,385 1 |
| Richard Rees, CFO | 18,750 | 3,417,079 2 |
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail in relation to the award of the SIP Shares to the Participating Directors.
Notes:
1 Includes shares held by a PCA of Mr Gulliford.
2 Includes shares held by PCAs of Mr Rees.
| a) | Name | Creo Medical Group plc | ||||
| b) | LEI | 213800H188ZDCWWXFA21 | ||||
| a) | Description of the financial instrument Identification code | Ordinary Shares of £0.001 each GB00BZ1BLL44 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares under Share Incentive Plan at the sole discretion of Fiduchi | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | N/A - Single transaction | ||||
| e) | Date of the transaction | 2026-07-01 | ||||
| f) | Place of the transaction | London Stock Exchange |
1 Details of person discharging managerial responsibilities / person closely associated
| a) | Name | Craig Gulliford | ||||
| 2 Reason for the notification | ||||||
| a) | Position / status | CEO | ||||
| b) | Initial notification / amendment | Initial notification | ||||
| a) | Name | Creo Medical Group plc | ||||
| b) | LEI | 213800H188ZDCWWXFA21 | ||||
| a) | Description of the financial instrument Identification code | Ordinary Shares of £0.001 each GB00BZ1BLL44 | ||||
| b) | Nature of the transaction | Award of Ordinary Shares (Matching Shares) under Share Incentive Plan | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | N/A - Single transaction | ||||
| e) | Date of the transaction | 2026-07-01 | ||||
| f) | Place of the transaction | Off-market | ||||
1 Details of person discharging managerial responsibilities / person closely associated
| a) | Name | Richard Rees | ||||
| 2 Reason for the notification | ||||||
| a) | Position / status | CFO | ||||
| b) | Initial notification / amendment | Initial notification | ||||
| a) | Name | Creo Medical Group plc | ||||
| b) | LEI | 213800H188ZDCWWXFA21 | ||||
| a) | Description of the financial instrument Identification code | Ordinary Shares of £0.001 each GB00BZ1BLL44 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares under Share Incentive Plan at the sole discretion of Fiduchi | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | N/A - Single transaction | ||||
| e) | Date of the transaction | 2026-07-01 | ||||
| f) | Place of the transaction | London Stock Exchange | ||||
1 Details of person discharging managerial responsibilities / person closely associated
| a) | Name | Richard Rees | ||||
| 2 Reason for the notification | ||||||
| a) | Position / status | CFO | ||||
| b) | Initial notification / amendment | Initial notification | ||||
| a) | Name | Creo Medical Group plc | ||||
| b) | LEI | 213800H188ZDCWWXFA21 | ||||
| a) | Description of the financial instrument Identification code | Ordinary Shares of £0.001 each GB00BZ1BLL44 | ||||
| b) | Nature of the transaction | Award of Ordinary Shares (Matching Shares) under Share Incentive Plan | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | N/A - Single transaction | ||||
| e) | Date of the transaction | 2026-07-01 | ||||
| f) | Place of the transaction | Off-market | ||||
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.